Akari Therapeutics (AKTX) Assets Average (2012 - 2026)
Akari Therapeutics (AKTX) posted quarterly Assets Average of $40.9 million for Q1 2026, down 19.44% year-on-year from $50.8 million in Q1 2025, and down 12.32% on a QoQ basis from $46.6 million in Q4 2025.
Akari Therapeutics (AKTX) Assets Average (2012 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Assets Average for 13 consecutive years, with $40.9 million the latest figure, recorded in Q1 2026.
- Quarterly Assets Average fell 19.44% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (down 19.44% YoY) and the FY2025 annual result came in at $49.2 million, up 79.28% from the prior year.
- Assets Average eased to $40.9 million in Q1 2026 per AKTX's latest filing, from $46.6 million in the prior quarter.
- Over the last five years, Assets Average for AKTX reached as high as $50.9 million in Q2 2025 and fell as low as $3.6 million in Q1 2024.
- A 4-year average of $27.2 million and a median of $26.6 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average jumped 1324.46% — and 2026, when it declined 19.44%.
- Year by year, Assets Average stood at $12.6 million in 2022, then jumped by 111.47% to $26.6 million in 2024, then jumped by 75.0% to $46.6 million in 2025, then slipped by 12.32% to $40.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $40.9 million, $46.6 million, and $48.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | 40.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.89 Mn |
| Dec 31, 2025 | 46.63 Mn |
| Sep 30, 2025 | 48.14 Mn |
| Jun 30, 2025 | 50.94 Mn |
| Mar 31, 2025 | 50.76 Mn |
| Dec 31, 2024 | 26.65 Mn |
| Sep 30, 2024 | 3.91 Mn |
| Jun 30, 2024 | 3.92 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2022 | 12.60 Mn |
| Jun 30, 2022 | 11.51 Mn |
| Dec 31, 2021 | 8.24 Mn |
| Jun 30, 2021 | 9.72 Mn |
| Dec 31, 2020 | 14.15 Mn |
| Sep 30, 2020 | 14.07 Mn |
| Jun 30, 2020 | 12.07 Mn |
| Mar 31, 2020 | 8.08 Mn |
| Dec 31, 2019 | 8.37 Mn |
| Sep 30, 2019 | 7.44 Mn |
| Jun 30, 2019 | 6.42 Mn |